Publikasi Scopus FKUI Tahun 2010 s/d 2020 (data Per 3 Februari 2021)

Arozal W., Watanabe K., Veeraveedu P.T., Thandavarayan R.A., Harima M., Sukumaran V., Suzuki K., Tachikawa H., Kodama M., Aizawa Y.
32067462200;55492737200;12796732500;23390800400;34971238300;35070365600;55624483910;7101868621;7403312707;36051317800;
Beneficial effects of angiotensin II receptor blocker, olmesartan, in limiting the cardiotoxic effect of daunorubicin in rats
2010
Free Radical Research
44
11
1369
1377
10
Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, 265-1 Higashijima, Akiha-ku, Niigata City 956-8603, Japan; Department of Pharmacology, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Department of Gastroenterology and Hepatology, Niigata University, Graduate School of Medical and Dental Sciences, Niigata, Japan; First Department of Internal Medicine, Niigata University, Graduate School of Medical and Dental Sciences, Niigata, Japan
Arozal, W., Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, 265-1 Higashijima, Akiha-ku, Niigata City 956-8603, Japan, Department of Pharmacology, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Watanabe, K., Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, 265-1 Higashijima, Akiha-ku, Niigata City 956-8603, Japan; Veeraveedu, P.T., Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, 265-1 Higashijima, Akiha-ku, Niigata City 956-8603, Japan; Thandavarayan, R.A., Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, 265-1 Higashijima, Akiha-ku, Niigata City 956-8603, Japan; Harima, M., Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, 265-1 Higashijima, Akiha-ku, Niigata City 956-8603, Japan; Sukumaran, V., Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, 265-1 Higashijima, Akiha-ku, Niigata City 956-8603, Japan; Suzuki, K., Department of Gastroenterology and Hepatology, Niigata University, Graduate School of Medical and Dental Sciences, Niigata, Japan; Tachikawa, H., First Department of Internal Medicine, Niigata University, Graduate School of Medical and Dental Sciences, Niigata, Japan; Kodama, M., First Department of Internal Medicine, Niigata University, Graduate School of Medical and Dental Sciences, Niigata, Japan; Aizawa, Y., First Department of Internal Medicine, Niigata University, Graduate School of Medical and Dental Sciences, Niigata, Japan
The aim was to evaluate the role of the combination of olmesartan, an angiotensin II (Ang II) receptor blocker (ARB), with daunorubicin (DNR) in reducing cardiac toxicity in rats. DNR was administered at a dose of 3 mg/kg/day every other day for 12 days. Olmesartan was administered orally every day for 12 days. Rats treated with DNR alone showed cardiac toxicity as evidenced by worsening cardiac function, elevation of malondialdehyde level in heart tissue and decreased in the level of total glutathione peroxidase activity; treatment with ARB reversed these changes. Furthermore, ARB treatment down-regulated matrix metalloproteinase-2 expression, myocardial expression of Ang II, attenuated the increased protein expressions of p67phox and Nox4 and reduced oxidative stress-induced DNA damage evaluated by expression of 8-hydroxydeoxyguanosine. In conclusion, the result demonstrated that Ang II and oxidative stress play a key role in anthracycline-induced cardiotoxicity and that treatment with ARB will be beneficial against DNR-induced cardiotoxicity. © 2010 Informa UK, Ltd.
angiotensin II receptor blocker; cardiotoxicity; Daunorubicin; olmesartan; oxidative stress
8 hydroxydeoxyguanosine; angiotensin receptor antagonist; anthracycline; daunorubicin; gelatinase A; glutathione peroxidase; olmesartan; reduced nicotinamide adenine dinucleotide phosphate oxidase 4; animal experiment; animal tissue; article; cardiotoxicity; controlled study; DNA damage; down regulation; drug effect; enzyme activity; heart; heart function; heart protection; male; nonhuman; oxidative stress; protein expression; rat; tissue level; Angiotensin II Type 1 Receptor Blockers; Animals; Antibiotics, Antineoplastic; Blotting, Western; Daunorubicin; Heart; Imidazoles; Immunohistochemistry; Male; Myocardium; Oxidative Stress; Rats; Rats, Sprague-Dawley; Tetrazoles; Rattus
10715762
FRARE
20815778
Article
Q1